NASCENT BIOTECH, INC. (OTCMKTS:NBIO) Files An 8-K Other EventsITEM 8.01 Other Events.
Nascent Biotech Inc. (the “Company”) previously announced that it had engaged HRA Capital to assist in raising capital for the Company on August 9, 2017. to the agreement between the parties, the Company announced today that it has terminated the agreement.
About NASCENT BIOTECH, INC. (OTCMKTS:NBIO)
Nascent Biotech Inc. is a clinical-stage biopharmaceutical company that develops monoclonal antibodies for the treatment of various forms of cancer. The Company is engaged in the research and development of the antibodies for control of brain and pancreatic cancer in humans. The Company focuses on biologic drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. The Company owns the license rights to a drug candidate, pritumumab, which it is developing. The Company is primarily focused on developing pritumumab for the treatment of patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma. Pritumumab is a monoclonal antibody. The Company has not generated revenues.
